Zofran Side Effects Linked to Heart Rhythm Problems, FDA Warns

Staff Writers

Add Your Comments

Federal health regulators are warning that side effects of Zofran, an anti-nausea drug sold by GlaxoSmithKline, could cause potentially fatal abnormal heart rhythms. 

The FDA issued a drug safety communication on September 15, alerting doctors and patients to changes in the electrical activity of the heart that have been linked to Zofran.

The potential heart problems from Zofran can lead to heart arrhythmia, including QT prolongation and Torsade de Pointes, which can be lethal. Although warnings have been on the drug’s label about the risk of QT prolongation, additional information is being required by the federal drug regulators.

Do You Know about…

Spinal Cord Stimulator lawsuits

Spinal cord stimulator lawsuits are being investigated for individuals who suffered unnecessary shocks, burns or other problems, often resulting in the need for additional surgery to remove the SCS.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION
Spinal-Cord-Stimulation-Lawsuit
Spinal-Cord-Stimulation-Lawsuit

Do You Know About…

Spinal Cord Stimulator lawsuits

Spinal cord stimulator lawsuits are being investigated for individuals who suffered unnecessary shocks, burns or other problems, often resulting in the need for additional surgery to remove the SCS.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION

GlaxoSmithKline has been ordered to update the label for Zofran to include more information about the risk of abnormal heart rhythms. The warning will urge doctors to avoid use of the drug in patients with congenital long QT syndrome and will recommend electrocardiogram monitoring for patients with electrolyte abnormalities, congestive heart failure, bradyarrhythmias, or in patients taking other drugs known to affect heart rhythms.

The FDA has also charged Glaxo with conducting a study to assess the extent of the heart rhythm side effects of Zofran. The agency expects the results of that study to be out by the summer of 2012.

Zofran (ondansetron) is approved to prevent nausea and vomiting. It is a member of a class of drugs called 5-HT3 receptor antagonists and works by blocking the actions of serotonin. It can be administered either as a pill, an oral solution, or as an injection.

The FDA recommends that patients taking Zofran seek immediate care if they experience an irregular heartbeat, shortness of breath, dizziness or fainting. However, the agency notes that individuals should not stop taking the medication without first talking to their healthcare professional.

Tags: GlaxoSmithKline, Heart Failure, Zofran

More Zofran Lawsuit Stories

4 Comments

Craig
I had no cardiac issues and immediately upon taking zofran have heart rhythm and rate issues.
Sandy
My dad was given zofran in the hospital and was fine before and right after he went into cardiac arrest and past away. This happened August 25th of this year.
Lana
On July 10th Husband given zofran with low posstium level & caused cardiac arrest and a small stroke Had to be shocked 6 times to get a pulse, recovery slow at this time. Is that a error in judgement on the er department & does that qualify for mal practice law suit? We now have medical bills to cover
terri
I have been having heart rhythym problems since taking zofran

This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Bard PowerPort Lawyers Make Final Preparations for Next MDL Bellwether Trial
Plaintiffs and defendants have submitted a joint schedule for a final pretrial conference before the second Bard PowerPort lawsuit bellwether trial over claims the port catheter is defectively designed.
Boston Scientific Spinal Cord Stimulator Lawyers To Meet With MDL Judge for Initial Conference Aug. 5
A federal judge appointed to oversee all federally consolidated Boston Scientific spinal cord stimulator lawsuits has called for an initial scheduling conference in early August.
Breast Reconstruction Mesh Market Expands Despite Lawsuits Over Synthetic Mesh Failures
Analysts expect wider use of breast reconstruction mesh through 2030, even as lawsuits raise questions about synthetic products, FDA approval and serious complications requiring additional surgery.